4SC AG of Germany has appointed Erich Enghofer, an oncology expert, to the newly created position of executive vice president oncology and haematology. In this role, he will be responsible for advancing the company’s candidate product, resminostat, a treatment for liver cancer. Previously, Dr Enghofer was head of the oncology business unit at Bayer HealthCare Deutschland. In this position he was instrumental in gaining marketing approval for sorafenib for liver cancer. Dr Enghofer was a member of the board of the German Cancer Society until May 2014. He is a member of several professional societies including the American Association for the Advancement of Science.
4SC announced the appointment on 3 July 2014.
Copyright 2014 Evernow Publishing Ltd